Literature DB >> 22531197

Serum procalcitonin concentration in the evaluation of febrile infants 2 to 60 days of age.

Jennifer U Woelker1, Madhumita Sinha, Norman C Christopher, Keith R Powell.   

Abstract

OBJECTIVE: Febrile infants younger than 60 days are at risk for serious bacterial infections (SBIs) and often undergo extensive laboratory investigation and hospitalization. We aim to determine the diagnostic value of serum procalcitonin (PCT) concentration for identification of febrile infants at low risk for SBI in comparison to the Rochester Criteria (RC).
METHODS: Infants 2 to 60 days of age with rectal temperature 38°C were enrolled between May 2004 and March 2007. Blood was obtained from each, and PCT was assessed using BRAHMS PCT LIA method. Information for identification of low-risk infants using RC was obtained. Negative predictive value, sensitivity, specificity, and likelihood ratio of PCT were compared with the RC. In univariate analysis, the components of RC and PCT were considered. Variables holding a significant association with the absence of SBI were included in a backward stepwise logistic regression model with SBI as the dependent variable, creating new low risk criteria.
RESULTS: One hundred fifty-five patients were enrolled. Thirteen (8.4%) had an SBI. Procalcitonin concentration at a cutoff value of 0.26 ng/mL is similar in sensitivity (92%) and better in specificity (64%) than RC. A combination of urine white blood cell and PCT was the best model in the regression analysis.
CONCLUSIONS: Procalcitonin concentration is a serological marker for identification of or exclusion of SBI in infants aged 2 to 60 days. The predictive value of PCT in combination with urinary white blood cell count may be clinically useful. A validation study is indicated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531197     DOI: 10.1097/PEC.0b013e318252c474

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  4 in total

Review 1.  Management of the Febrile Young Infant: Update for the 21st Century.

Authors:  Christopher Woll; Mark I Neuman; Paul L Aronson
Journal:  Pediatr Emerg Care       Date:  2017-11       Impact factor: 1.454

2.  Use of Procalcitonin in a Febrile Infant Clinical Pathway and Impact on Infants Aged 29 to 60 Days.

Authors:  Kaitlin Widmer; Sarah Schmidt; Leigh Anne Bakel; Michael Cookson; Jan Leonard; Amy Tyler
Journal:  Hosp Pediatr       Date:  2021-03

3.  Improving the Evidence-based Care of Febrile Neonates: A Quality Improvement Initiative.

Authors:  Lily Yu; Rachel S Bensman; Selena L Hariharan; Constance M McAneney; Victoria Wurster Ovalle; Eileen Murtagh Kurowski
Journal:  Pediatr Qual Saf       Date:  2022-08-01

4.  Procalcitonin at 12-36 hours of fever for prediction of invasive bacterial infections in hospitalized febrile neonates.

Authors:  Anne-Sophie Romain; Romain Guedj; Anais Chosidow; Nicolas Mediamolle; Aurélie Schnuriger; Sophie Vimont; Charlène Ferrandiz; Nicolas Robin; Marie-Hélène Odièvre; Emmanuel Grimprel; Mathie Lorrot
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.